Oxilio completes first clinical trial with OXL001 at Quotient Sciences - Nottingham
Oxilio completes Phase 1 clinical trial with OXL001 at Quotient Sciences - Nottingham with favourable safety and pharmacokinetic data.
OXFORD, UK; 20 June 2023 – Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, today announced favourable safety and pharmacokinetic data from a single-part, five-period, sequential, open-labelled Phase 1 study of OXL001 in healthy male volunteers that is being conducted at Quotient Science. The objectives of the study were met as follows:
- OXL001 capsules were considered to be safe at all doses tested
- Dose proportional plasma exposures were achieved via a novel lipidic formulation technology, exclusively licenced from TRx Biosciences
- Data generated will inform the formulation and dosing strategy for future OXL001 studies
The Company also announces the commencement of an additional pre-clinical programme that will enhance understanding of how OXL001 formulations can target preferential uptake into specific tumour-surrogate tissues following oral delivery. Results in the coming months will enable further optimisation of OXL001 at this stage of clinical development to maximise the product’s potential in the treatment of cancer.
Dr Mark Egerton, CEO of Quotient Sciences, added:
“We are pleased that the Phase 1 healthy volunteer study being conducted at Quotient Sciences’ Nottingham facility has delivered rapid and favourable results for Oxilio’s OXL001 program. We will continue supporting OXL001 with our Translational Pharmaceutics® platform with fully integrated clinical assessments in order to aid in accelerated development timelines and downstream advancement to patients.”
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast. For more information, please visit quotientsciences.com.
Quotient Sciences Company Contact
Executive Director of Global Marketing
Oxilio is a pioneering pharmaceutical drug development company improving cancer treatment through rapid, cost-effective drug development. Our mission is to identify, repurpose, and commercialize existing drugs to address unmet needs in cancer therapy. We find new uses for old drugs, a proven approach that involves less risk, time, and cost to bring a drug to the marketplace. Through repurposing, reformulation, and gold-standard modeling and simulations, we are fast-tracking disruptive drug development at speed and at low cost.
Oxilio Company Contact
About TRx Biosciences
TRx Biosciences’ technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer, CNS and respiratory diseases, and diseases of the immune system using a clinically and commercially proven approach. Our bio-enabling delivery mechanism addresses bioavailability, solubility and permeability limitations simultaneously, whilst allowing drugs to be highly targeted towards specific cells and tissues to best leverage their pharmacology. Our data demonstrates that TRx technology has the potential to significantly enhance the design and development of existing and future small molecule-based therapies.
For more information, please visit trxbiosciences.com
Company Contact: email@example.com